Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Long-term Investments
Investments the company intends to hold for more than a year.
Apogee Therapeutics, Inc.NASDAQ: APGE
Long-term Investments · Q2 FY2026 · quarter ended Jun 2026
Long-term investments rises 178.1% from a year ago
Long-term investments stood at $321.94M at the end of Q2 FY2026, up 178.1% from a year earlier.
Context
- Long-term investments amounted to 24.1% of total assets at the end of Q2 FY2026, up 6.5 pp from a year earlier.
- Long-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether long-term investments keeps rising in the next quarterly balance sheet after a +178.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 210.42M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Long-term Investments vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +178.1% is the highest of 6, against a peer median of +83.1%.
- Long-term investments amounts to 24.1% of total assets for APGE, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $321.94M USD | +178.1% | — | 24.1% | |
| Mar 2026 | $257.12M USD | +83.1% | — | 40.1% | |
| Sep 2026 | $202.68M USD | +118.0% | -33.9% | 16.9% | |
| Mar 2026 | $127M USD | +85.2% | -26.6% | 9.8% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥37.05M CNY | +9.4% | +26.0% | 0.9% |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
| Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding APGE) | — | +83.1% | -26.6% | 0.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.